Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Frontiers in Pharmacology Année : 2021

Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances

Charles Khouri
Bruno Revol
Matthieu Roustit
Jean-Luc Cracowski

Résumé

Background: A plethora of methods and models of disproportionality analyses for safety surveillance have been developed to date without consensus nor a gold standard, leading to methodological heterogeneity and substantial variability in results. We hypothesized that this variability is inversely correlated to the robustness of a signal of disproportionate reporting (SDR) and could be used to improve signal detection performances. Methods: We used a validated reference set containing 399 true and false drug-event pairs and performed, with a frequentist and a Bayesian disproportionality method, seven types of analyses (model) for which the results were very unlikely to be related to actual differences in absolute risks of ADR. We calculated sensitivity, specificity and plotted ROC curves for each model. We then evaluated the predictive capacities of all models and assessed the impact of combining such models with the number of positive SDR for a given drug-event pair through binomial regression models. Results: We found considerable variability in disproportionality analysis results, both positive and negative SDR could be generated for 60% of all drug-event pairs depending on the model used whatever their truthfulness. Furthermore, using the number of positive SDR for a given drug-event pair largely improved the signal detection performances of all models. Conclusion: We therefore advocate for the pre-registration of protocols and the presentation of a set of secondary and sensitivity analyses instead of a unique result to avoid selective outcome reporting and because variability in the results may reflect the likelihood of a signal being a true adverse drug reaction.
Fichier principal
Vignette du fichier
BPH_FIP_2021_Khouri.pdf (1.74 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03323000 , version 1 (20-08-2021)

Licence

Paternité

Identifiants

Citer

Charles Khouri, Thuy Nguyen, Bruno Revol, Marion Lepelley, Antoine Pariente, et al.. Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances. Frontiers in Pharmacology, 2021, 12, pp.668765. ⟨10.3389/fphar.2021.668765⟩. ⟨hal-03323000⟩

Collections

UGA MIAI ANR U1219
27 Consultations
69 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More